Yes, eligible adults with early Alzheimer's can now start Leqembi with a weekly injection under the skin. Leqembi Iqlik, a subcutaneous form of lecanemab-irmb, is made for mild cognitive impairment or mild dementia due to Alzheimer's disease. On July 13, 2026, the FDA approved it as an initiation dose usable from day one, according to the Eisai and Biogen approval notice. For adult children, that change means asking a specialist about testing, brain-scan safety checks, and home injection training.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is my parent eligible?
- What does the weekly dose involve?
- How are brain risks watched?
- When can treatment begin at home?
Is my parent eligible?
Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Amyloid buildup must be confirmed by PET, spinal fluid, or validated testing, according to the European Medicines Agency summary. Ask where your parent falls on that scale.
Ask which amyloid test the center uses and how long results take. Bring prior memory scores, PET or spinal-fluid reports, and the full drug list. Use this checklist for the visit:.
- Diagnosis stage and amyloid result on file
- ApoE ε4 status and bleeding-risk review
- MRI schedule and who orders the scans
What does the weekly dose involve?
The starting regimen is 500 mg once weekly by autoinjector, given as two back-to-back 250-mg injections, according to the Eisai and Biogen dosing information. Each injection takes about 15 seconds.
Eisai and Biogen state after 18 months of initiation treatment, patients may continue initiation dosing or switch to 360 mg weekly under the skin. Ask the specialist which path fits your parent and when that choice comes up.
How are brain risks watched?
Lecanemab carries an FDA boxed warning for amyloid-related imaging abnormalities with swelling and bleeding. Risk is highest in people with two copies of ApoE ε4. ApoE ε4 testing and baseline plus scheduled brain MRIs are required, according to the FDA safety labeling record.
Ask about headache, confusion, vision change, or other warning signs that need prompt calls. Ask who reads the MRIs and how results pause or stop dosing. Keep a one-page schedule of scans and phone numbers on the fridge.
When can treatment begin at home?
Eisai and Biogen planned U.S. launch for late August 2026 through specialty pharmacy, which affects when training slots open.
Ask when your center expects supply and how injection training is booked. The Alzheimer's Association notes home injection can replace biweekly infusion visits from the start, but amyloid confirmation, ARIA counseling, MRI checks, and supervised training still apply. Bring the drug list, MRI history, and ApoE result to that first specialist visit.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Questions Memory Clinic Patients Can Bring to a Clinician
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Questions Memory Clinic Patients Can Bring to a Clinician
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Questions Memory Clinic Patients Can Bring to a Clinician
